Extended indication Non-squamous NSCLC, 1L.
Therapeutic value No judgement

Product

Active substance Veliparib
Domain Oncology and Hematology
Main indication Lung cancer
Extended indication Non-squamous NSCLC, 1L.
Manufacturer Abbvie
Route of administration Oral
Therapeutical formulation Capsule
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Orphan drug No

Therapeutic value

Therapeutic value No judgement
Duration of treatment Not found

Expected patient volume per year

Patient volume

< 811

Market share is generally not included unless otherwise stated.

References NKR
Additional remarks NKR 2016: 9289 diagnoses NSCLC, stadium 3 en 4. 35% niet-plaveiselcel. 60% onvangt eerstelijnsbehandeling, waarvan 50% chemotherapie. Dit komt neer op een totaal van 811 patiƫnten.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.